skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
Material Type:
Article
Add to My Research

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

The Lancet (British edition), 2023-03, Vol.401 (10378), p.733-746 [Peer Reviewed Journal]

2023 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(23)00221-0

Full text available

2
Sotorasib versus docetaxel for previously treated non-small- cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
Material Type:
Article
Add to My Research

Sotorasib versus docetaxel for previously treated non-small- cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

LANCET, 2023-03, Vol.401 (10378), p.733-746 [Peer Reviewed Journal]

ISSN: 0140-6736 ;EISSN: 1474-547X

Full text available

3
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS G12C mutation: a randomised, open-label, phase 3 trial
Material Type:
Article
Add to My Research

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS G12C mutation: a randomised, open-label, phase 3 trial

The Lancet (British edition), 2023-03, Vol.401 (10378), p.733 [Peer Reviewed Journal]

Copyright © 2023 Elsevier Ltd. All rights reserved. ;2023. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(23)00221-0 ;PMID: 36764316

Full text available

Searching Remote Databases, Please Wait